In patients with large vessel occlusion (LVO), marked and frequently iatrogenic blood pressure reductions occur around the time of initial imaging and prior to endovascular therapy (EVT), and may present a potential target for therapeutic intervention.
Decrease in blood pressure before reperfusion may increase the risk of infarct progression and poor functional outcome. A new study looked at the relation of blood pressure reductions during the hyperacute period of stroke with infarct progression and functional outcome [1]. Patients with LVO undergoing EVT were prospectively enrolled. To study timing of blood pressure reductions, high-frequency blood pressure and haemodynamic monitoring were used. Outcomes were analysed of 45 patients who underwent continuous blood pressure monitoring. Mean age was 72 years, 26 (58%) were female, mean NIH Stroke Scale score was 13.
There was a marked blood pressure reduction around the time of imaging, from which patients recovered, as well as a sustained decrease in blood pressure after groin puncture, without return to baseline. After adjusting for age and admission NIH Stroke Scale score, mean arterial pressure difference from baseline (ΔMAP) was independently associated with infarct growth (P=0.02). On average, there was a 16 mL increase in infarct volume for every 10 mmHg reduction in ΔMAP (P=0.054) in the hyperacute phase before reperfusion. The authors suggested that the observed changes in haemodynamic variables throughout the acute stroke period indicate that fluid resuscitation could be used for haemodynamic optimisation.
- Peshwe KU, et al. Blood Pressure Reductions in the Hyperacute Phase of Large Vessel Occlusion Ischemic Stroke Are Associated With Infarct Progression And Poor Functional Outcome. S6.003, AAN 2021 Virtual Congress, 17-22 April.
Copyright ©2021 Medicom Medical Publishers
Posted on
« GLOW: Ibrutinib plus venetoclax showed superior efficacy as first-line treatment of CLL Next Article
Effectiveness of public awareness campaigns on stroke signs »
Table of Contents: AAN 2021
Featured articles
Letter from the Editor
Interview with AAN President Dr James C. Stevens
COVID-19 and Neurology
The neurological impact of COVID-19
Chemosensory dysfunction often persistent after COVID-19
Pandemic results in decreased global stroke care
Stroke uncommon in critically ill COVID-19 patients
Cognitive Impairment and Dementias
Obstructive sleep apnoea associated with lower cognition
NfL is a better marker for neurodegeneration than T-tau
Monoclonal antibody rapidly reduces brain amyloid
Epilepsy
Extraordinary transformation of epilepsy care in Ontario
No neurodevelopmental effects of foetal antiseizure medication
Migraine and Other Headaches
Long-term safety of atogepant as migraine prophylaxis
Multiple Sclerosis
Dysmetabolism may drive MS progression
Predicting long-term prognosis in paediatric MS patients
Neuromuscular Disorders
Functional and survival benefits of AMX0035 in ALS
Parkinson’s Disease and Other Movement Disorders
Autoimmune mechanisms implicated in Parkinson’s disease
Novel non–D2-receptor-binding treatment for Parkinson’s disease psychosis
Troriluzole for spinocerebellar ataxia
Stroke
Can linoleic acid help prevent stroke?
No association between SSRIs and risk of ICH
Other Topics
Vutrisiran for hATTR amyloidosis with polyneuropathy
10 kHz spinal cord stimulation for painful diabetic neuropathy
Related Articles
Gene therapy for Leber hereditary optic neuropathy
Vutrisiran for hATTR amyloidosis with polyneuropathy
Lower-sodium oxybate for hypersomnia
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy